/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Introduction We are a blank check company incorporated in the British Virgin Islands ( BVI ) on June 18, 2021, under the original name of Central Acquisition Limited as a BVI business company with limited liability (meaning that our public shareholders have no liability, as shareholders of our company, for the liabilities of our company over and above the amount paid for their shares). We were …
$12.01
$0.08 (-0.66%)
Price from 40 days ago
At 36x earnings, the current multiple leaves limited room for execution misses or growth deceleration.
36.1x earnings. Not cheap, the quality is already reflected in the price. Upside from here requires either margin expansion or growth re-acceleration, not just continuation.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
$856K
▼ -74.2% YoY
Op. Margin
—
ROIC
—
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$754K
▲ +31.4% YoY
Net Debt
-$11K
Net Cash Position
Cash & Equiv.
$11K
Continue Research
SourceComputed from the 10-Q filed 14 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 15 Aug 2026. How this is calculated.
Price from market data, last close as of 11 Aug 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
At a P/E of 36.1, Keen Vision Acquisition (KVAC)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
That depends on valuation and quality together, not either alone. you should weigh KVAC's valuation. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.